Pacalis Therapeutics is a biotechnology company developing novel small molecule therapeutics for central nervous system disorders. Their pipeline targets the serotonin 5-HT2A receptor to promote neuroplasticity and improve treatment outcomes for conditions like Major Depressive Disorder, Substance Use Disorder, and PTSD.
Funding
Funding not disclosed
Founders
Product
Problem
A significant portion of the global population is affected by mental health conditions, including depression, substance use disorder, and PTSD, with current treatment options often proving insufficient. This unmet need highlights a critical gap in accessible and effective therapeutic interventions for these widespread disorders.
Solution
Pacalis Therapeutics is a neuroscience biotechnology company focused on developing novel small molecule therapeutics for central nervous system (CNS) disorders. The company's pipeline targets the serotonin 5-HT2A receptor, aiming to promote neuroplasticity and deliver improved treatment outcomes. Pacalis is developing oral medications designed to address conditions such as Major Depressive Disorder (MDD), Substance Use Disorder (SUD), and Post-Traumatic Stress Disorder (PTSD). By leveraging expertise in pharmacology and neuroscience, Pacalis aims to create first-in-class and best-in-class therapies to transform mental healthcare.
Target Audience
Pacalis Therapeutics targets individuals suffering from major depressive disorder, substance use disorder, and PTSD, as well as healthcare providers and researchers seeking advanced therapeutic options for mental health conditions.
Features
- Small molecule drug candidates targeting the serotonin 5-HT2A receptor.
- Compounds designed for CNS activity to promote neuroplasticity.
- Focus on oral administration for patient convenience.
- Pipeline development for Major Depressive Disorder (MDD).
- Pipeline development for Substance Use Disorder (SUD).
- Pipeline development for Post-Traumatic Stress Disorder (PTSD).